Given that the limited survival time was calculated for patients in the late stage of melanoma and the increasing trends of the incidence, further clinical trials for an lncRNA POU3F3-targeted therapy is considered as a promising strategy for melanoma treatment. This evidence concerns the gene POU3F3 and melanoma.